Navigation Links
Forge Therapeutics Announces Novel Antibiotic Presentation at the American Society of Microbiology Conference on Antibacterial Development
Date:12/12/2016

SAN DIEGO, Dec. 12, 2016 /PRNewswire/ -- Forge Therapeutics, Inc. announced today that new preclinical data on its novel class of antibiotic targeting LpxC for treating infections by Gram-negative drug resistant bacteria will be presented at the American Society of Microbiology Conference held in Washington, DC from December 11-14, 2016.

Presentation details:


Conference Title:

ASM Conference on Antibacterial DevelopmentPoster presentation:

Monday, December 12 from 7:00pm to 8:30pmPoster title:

#35 Antimicrobial activity of non-hydroxamate LpxC inhibitorsConference location:

Omni Shoreham Hotel
2500 Calvert Street, NM,
Washington, DC 20008

Conference website:   http://conferences.asm.org/index.php/upcoming-conferences/asm-conference-on-antibacterial-development

About LpxC
Drug resistant Gram-negative bacteria are regarded as an extremely dangerous public health threat, therefore, novel antibiotics targeting Gram-negative bacteria are desperately needed. LpxC is a highly sought after target only found in Gram-negative bacteria.  Forge has discovered novel small molecule inhibitors of LpxC that are potent in vitro, efficacious and tolerated in vivo, and effective against drug resistance mechanisms including mcr-1, KPC, and NDM.  

About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit www.ForgeTherapeutics.com.

Contact:
Info@ForgeTherapeutics.com

Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-announces-novel-antibiotic-presentation-at-the-american-society-of-microbiology-conference-on-antibacterial-development-300376235.html


'/>"/>
SOURCE Forge Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
2. Tor/Forge Launches THE CURE, a Riveting Thriller in the Tradition of Michael Crichton, by the New York Times Bestselling Author of WIRED.
3. Never forget a face
4. Bynder and HubCast Forge Global Partnership for Transformative “Concept to Delivery” Solution
5. Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery
6. Forge Therapeutics Enters Into a Pilot Study with Janssen Research & Development, LLC, to Discover Novel Metalloprotein Inhibitors
7. Forge Therapeutics Co-Founder to Present at the 250th American Chemical Society National Meeting
8. Forge Therapeutics Scientific Co-Founder Bestowed Prestigious National Chemistry Award
9. PointCross Life Sciences And Smithers Avanza Forge Strategic Partnership For SEND Solutions
10. Childhood Leukemias Forged by Different Evolutionary Forces than in Older Adults
11. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Palo Alto, CA, USA (PRWEB) , ... March 29, 2017 , ... ... experts in various regulatory subjects has announced its 3rd Annual Medical Device Summit 2017 ... 2017 at the Omni Parker House Hotel, in Boston, MA. , The Omni Parker ...
(Date:3/29/2017)... 29, 2017  Halozyme Therapeutics, Inc. (NASDAQ: HALO), ... therapies, today announced that an Oncologic Drug Advisory ... voted 11 to 0 that the benefit/risk of ... favorable for patients in the proposed indications of ... lymphocytic leukemia. The FDA action date is June ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, ... disperses a quarterly travel award to noteworthy scientists who will be presenting research ... its new round of awards are being given to two postdoctoral fellows studying ...
(Date:3/29/2017)... ... 29, 2017 , ... Bactana Animal Health, a company developing natural products aimed ... enhancement of the gut microbiota, today announced the closing of its first round of ... Sustainable Income Capital Management, LLC and a number of private investors. The company will ...
Breaking Biology Technology:
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):